Blood and marrow transplant - SA Health Approved Cancer Chemotherapy Protocol Register

Mobilisation

Mobilisation
Protocol Administration at chemotherapy unit level Review Date
Mobilisation of peripheral blood stem cells using plerixafor and G-CSF High February 2024
Peripheral blood stem cell (PBSC) mobilisation protocol CYCLOPHOSPHamide High August 2022

Allogeneic

Allogeneic protocols
Protocol Administration at chemotherapy unit level Review date
Allogeneic intermediate intensity conditioning protocol (cord) CYCLOPHOSPHamide fludarabine thiotepa and total body irradiation (TBI) High August 2023
Allogeneic myeloablative conditioning protocol busulfan and fludarabine High August 2024
Allogeneic myeloablative conditioning protocol CYCLOPHOSPHamide and busulfan (reversed order) High August 2022
Allogeneic myeloablative conditioning protocol CYCLOPHOSPHamide and total body irradiation (TBI) High August 2022
Allogeneic non myeloablative conditioning protocol (Haploidentical) CYCLOPHOSPHamide fludarabine and total body irradiation (TBI) High August 2022
Allogeneic reduced intensity conditioning protocol fludarabine and melphalan High August 2021

Autologous

Patient treatment scheduling may differ between sites depending on local procedures

Autologous
Protocol Administration at chemotherapy unit level Review Date
Autologous conditioning protocol BEAM (carmustine etoposide cytarabine melphalan) High August 2022
Autologous conditioning protocol busulfan and melphalan High August 2024
Autologous conditioning protocol germ cell tumour TICE treatment overview High August 2022
Autologous conditioning protocol germ cell tumour TICE (cARBOplatin and Etoposide) (part 2) High August 2022
Autologous conditioning protocol germ cell tumour TICE (PACLItaxel and IFOSFamide) (part 1) High August 2022
Autologous conditioning protocol high dose melphalan 140 mg/m2 High August 2022
Autologous conditioning protocol high dose melphalan 200 mg/m2 High August 2022
Autologous conditioning protocol primary CNS lymphoma carmustine and thiotepa High August 2024

Notes

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Non-formulary drug included in the protocol
  4. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.